{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000007","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.267625+00:00","generated_at":"2026-06-07T02:24:26.697689+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zentalis licenses ROR1 ADC ZPC-21 to Immunome for $35M upfront, up to $275M milestones","bullets":["Exclusive worldwide license of preclinical ROR1 ADC ZPC-21 and proprietary ADC platform to Immunome.","Zentalis receives $35M upfront in cash and Immunome common stock; eligible for up to $275M milestones plus mid-to-high single-digit royalties.","Immunome plans to submit IND for ZPC-21 in 1Q 2025.","Zentalis to focus resources on advancing azenosertib (WEE1 inhibitor) in multiple clinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000007","json":"https://secwatch.observer/filing/0001725160-24-000007.json","markdown":"https://secwatch.observer/filing/0001725160-24-000007.md","text":"https://secwatch.observer/filing/0001725160-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000007/0001725160-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000007/zntl-20240105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:24:26.697689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}